Virus-Like Particles (VLP’s) Market Research Report 2021: Forecast to 2028 with COVID-19 Impact and Global Analysis – ResearchAndMarkets.com

Dublin – (work wire) – “Virus Like Particulates (VLP) Market Forecast to 2028 – Impact of COVID-19 and Global Analysis” has been added to ResearchAndMarkets.com Show.

Virus Like Particulates (VLP’s) Market is expected to reach USD 7,858.82 Million by 2028 from USD 4,601.84 Million in 2021; It is expected to grow at a compound annual growth rate of 7.9% from 2021 to 2028.

Consistent research and development activities significantly lead to the growth of the market as a whole. VLPs have gained interest from many researchers, especially virologists and immunologists. VLP-based vaccines are more immunogenic and safer than conventional vaccines because they cannot replicate, recombine, or undergo re-screening due to a lack of infectious DNA or RNA.

However, the feasibility of VLPs as antigen carriers is questionable and complicated due to the associated difficulties that lead to slow growth in the global market. Therefore, the Frontiers SA report notes that for the mutation of viruses combined with their adjuvant effect and inflammatory response, researchers should be evaluated for the development of each new VLP vaccine.

The global Virus-Like Particles (VLP’s) market is segmented on the basis of product type, source, and application. On the basis of product type, the virus-like particles market is segmented as hepatitis, cancer/human papillomavirus, and Gaucher disease. The hepatitis segment will constitute a significant market share during the period 2021-2028.

For example, according to data published by the Hepatitis B Foundations in 2021, around two billion people are infected with hepatitis B virus worldwide. To counter such a situation, the use of commercial VLP vaccines has proven to be effective in treating hepatitis. Examples of commercial VLP vaccines include “Recombivax” and “Engerix”.

These are the two recently marketed VLP-based vaccines for hepatitis B and “Gardasil” and “Cervarix” which are both licensed VLP-based vaccines for HPV. Today, VLP-based vaccines against hepatitis C virus, Ebola, Lassa virus, Hantavirus, Marburg, SARS coronavirus, and chikungunya virus, among others, are in various stages of development.

By source, the virus-like particles market is segmented into yeast, insect cells, plants, and others. Depending on the source, the yeast segment will record a dominating share of the overall market in the coming years. Yeast cells are frequently used to express recombinant proteins and have been widely used in VLP vaccine production.

This is mainly due to advantages such as rapid cell growth, high protein expression yield, ease of expansion, cost-effective production, and high degree of post-translational modification (PTM). The Food and Drug Administration (FDA) has approved two VLP-based vaccines — Engerix-B (HBV vaccine) and Gardasil (HPV vaccine) — that were produced using yeast expression systems.

By application, the virus-like particles market is segmented into vaccines and therapeutics. The vaccine segment will retain a significant share of the market in 2021, and is likely to continue its dominance in the market during the forecast period as well.

VLP-based vaccines were developed as an alternative to conventional vaccines due to their safety, flexibility, and distinct immunologic properties. Transmission of infectious or fatal viruses such as HCV poses a serious threat to populations worldwide.

The introduction of the HCV vaccine using simulation models was expected in a high-risk population with a significant impact on reducing the incidence of hepatitis C. For example, to avoid such a situation, a simulation model was developed by the government focusing on the vaccination program with the aim of reducing the incidence of infection Hepatitis C virus.

Simulations have demonstrated a proven track record in reducing the spread of hepatitis C through the VLP vaccine. Even with modest efficacy and coverage, the VLP vaccine significantly reduces the incidence of hepatitis C in the population as the vaccine has efficacy of up to 50–80%, and targets high-risk intravenous drug users, can significantly reduce the incidence of hepatitis C in the population.

Therefore, a vaccine based on VLPs represents a safe and highly immunogenic vaccine delivery platform capable of stimulating a robust adaptive immune response.

Key market dynamics

Market Drivers

  • Spread of infectious viral diseases

Expanding the role of virus-like particles in clinical developments and studies

  • market restrictions

  • Availability of alternative technologies to produce a viral vaccine

Market Opportunities

  • Potential applications in therapeutics and diagnostics

future trends

  • Constant demand for innovative and effective products

mentioned companies

  • Merck & Co., Inc.

  • GlaxoSmithKline Corporation.

  • Pfizer Inc

  • Dynavax Technologies

  • Sanofi

  • Wantay Biopharm

  • Serum Institute of India Pvt. Ltd.

  • your house spices

  • LG Chem

  • VBI . Vaccines Company

For more information on this report, visit https://www.researchandmarkets.com/r/e6uhd5.

Leave a Comment